Biotech firm Mabpharm launches initial public offering in Hong Kong
The China-based biotechnology company, Mabpharm, has launched an initial public offering (IPO) in Hong Kong, China Money Network reports.
Mabpharm, who was first established in 2015, becomes the latest in a number of biotech companies that have filed for Hong Kong IPOs.
As the Hong Kong bourse changed its rules to allow the listings of biotech firms that don’t achieve the criteria of the Main Board’s financial eligibility tests in April, it has caused a selection of Chinese biotech companies, such as Ascentage Pharma Group and Hangzhou-based Ascletis Pharma to get involved.
The firm primarily targets the research, development and production of monoclonal antibody drugs in the fight against cancer and autoimmune diseases.
- Alibaba funds $3bn from SoftBank to enhance food delivery business
- Xiaomi plans to sell more premium smartphones to meet increased demand
- Alibaba set to invest $121mn in Guizhou Ensure Chain Pharmacy
Mabpharm currently has a number of drug candidates made up of nine monoclonal antibody drugs, which is thought to have consisted of 5.4% of the biologics market in China last year that is believed to be worth $1.7bn.
From 2013 to 2017, the firm announced in its IPO prospectus that the Chinese biologics market increased by 26.2% which was significantly higher than the 7.4% global growth during the same timescale.
- PwC: What Hong Kong’s workforce want from business leadersLeadership & Strategy
- Hong Kong is crowned world’s most crypto-ready countryLeadership & Strategy
- Greater Bay Area is potential workplace pull for HongkongersLeadership & Strategy
- How Hong Kong can retain its status as leading financial hubLeadership & Strategy